title: Successful medical treatment with octreotide for chyloperitoneum following paraaortic lymphadenectomy in the treatment of gynecologic malignancies: a report of 2 cases.
abstract: BACKGROUND
  Chyloperitoneum is a rare and challenging complication following systematic pelvic and retroperitoneal lymphadenectomy in the management of gynecologic malignancies. Despite its infrequent occurrence, postoperative chyloperitoneum is associated with significant morbidity.
  
  
  METHODS
  Two patients developed chyloperitoneum following paraaortic lymphadenectomy for ovarian carcinoma and endometrial carcinoma, respectively. In both cases early infusion of octreotide, a somatostatin analogue, resulted in rapid resolution of chyloperitoneum. There was no evidence of ascites at 6 and 10 months' follow-up, respectively.
  
  
  CONCLUSIONS
  It is suggested that the early administration of octreotide in the course of chyloperitoneum following paraaortic lymphadenectomy in the treatment of gynecologic malignancies is highly effective and should be initiated early in the course of treatment before any invasive options are considered.
authors.affiliation: Department of Obstetrics and Gynecology, Hyogo Prefectural Tsukaguchi Hospital, Amagasaki, Kobe Medical Center and Kobe University Graduate School of Medicine, Sumaku, Kobe, Japan. kyousuket@dolphin.ocn.ne.jp
authors.forename: Kyousuke
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Kanae
authors.initials: K
authors.lastname: Fujiwara
authors.forename: Taro
authors.initials: T
authors.lastname: Tsujino
authors.forename: Hiroki
authors.initials: H
authors.lastname: Morita
mesh_terms: D000230:Adenocarcinoma / Q000601:surgery; D018262:Adenocarcinoma, Clear Cell / Q000601:surgery; D000368:Aged; D001012:Aorta, Abdominal; D002915:Chylous Ascites / Q000188:drug therapy* / Q000209:etiology*; D016889:Endometrial Neoplasms / Q000601:surgery; D005260:Female; D005833:Genital Neoplasms, Female / Q000601:surgery*; D006801:Humans; D007044:Hysterectomy; D008197:Lymph Node Excision / Q000009:adverse effects*; D008198:Lymph Nodes; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000601:surgery; D010052:Ovariectomy; D011183:Postoperative Complications / Q000188:drug therapy; D058994:Salpingectomy
chemical_list: D015282:Octreotide